Ex-Legacy Pharmaceuticals machinery and equipment up for sale, says Hilco Industrial
Industrial assets purchaser is offering high-capacity production line equipment formerly owned by bankrupt CMO
Industrial assets purchaser Hilco Industrial Acquisitions says it is trying to bring back to the pharmaceutical market all machinery and equipment it purchased from bankrupt CMO Legacy Pharmaceuticals in a liquidation sale in March.
Switzerland-based Legacy, which specialised in fill/finish of sterile and semi-solid drug products, filed for bankruptcy in December 2020, resulting in over 200 job losses. At the time the company said the move had been driven by non-payment of important customers.
However, in October 2020, Legacy had been forced to stop manufacturing sterile drugs by Swissmedic after its facility failed an inspection by the Swiss drug regulator.
Darko Pepovski, Vice President Sales & Marketing of Hilco in the Netherlands, said his challenge is to bring the high-capacity production lines back to the market.
“To do so, we have started a worldwide marketing and sales campaign, making potential buyers in the pharmaceutical and associated industries aware of the opportunity to acquire the excellently maintained, late-model equipment needed, to increase their production capacities, especially in these days of high demand for injectables due to COVID,” he said.
To view the online auction for the ex-Legacy equipment, click here.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance